Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dacomitinib plus Anlotinib in EGFR-mutated NSCLC
NCT05271916Phase 2Recruiting
- Sponsor
- Shanghai Chest Hospital
- Start
- Oct 2022
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of anlotinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Shanghai Chest Hospital. Primary endpoints: Overall safety profile and Progression Free Survival. Started Oct 2022; status: recruiting.
02
Drugs
anlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05271916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05271916.